It is used for the treatment of hepatocellular carcinoma where cancer cells have specific receptors, mainly including epidermal growth factor receptor (EGFR) inhibitors, vascular endothelial growth factor receptor (VEGFR) antagonists, etc. Sorafenib was the only molecularly targeted drug approved for the treatment of advanced hepatocellular carcinoma in China. The gene discussed is KDR; the disease is cancer.